Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Outcome and characteristics of non-measurable myeloma : A cohort study with population-based data from the Swedish Myeloma Registry

Wålinder, Göran ; Samuelsson, Jan ; Näsman, Per ; Hansson, Markus LU orcid ; Juliusson, Gunnar LU ; Forsberg, Karin ; Svensson, Ronald ; Linder, Olle ; Carlson, Kristina and Kristinsson, Sigurdur Y. , et al. (2020) In European Journal of Haematology 104(5). p.376-382
Abstract

Objective: We describe survival in patients with oligo- and non-secretory multiple myeloma (MM). We refer to the whole group as non-measurable MM and compare it with secretory MM. Methods: Oligo-secretory MM was defined as M protein in serum <10 g/L and M protein in urine <200 measured as mg/day, mg/liter or mg/mmol creatinine. If patients had no M protein, they were defined as non-secretory. The groups were also subdivided by Free Light Chains (SFLC) level and ratio. Results: Out of 4325 patients with symptomatic MM in the Swedish Myeloma Registry during 2008-2016 eligible for the study, 389 patients (9%) had non-measurable MM. Out of these, 253 patients (6%) had oligo-secretory and 136 (3%) had non-secretory MM. Median survival... (More)

Objective: We describe survival in patients with oligo- and non-secretory multiple myeloma (MM). We refer to the whole group as non-measurable MM and compare it with secretory MM. Methods: Oligo-secretory MM was defined as M protein in serum <10 g/L and M protein in urine <200 measured as mg/day, mg/liter or mg/mmol creatinine. If patients had no M protein, they were defined as non-secretory. The groups were also subdivided by Free Light Chains (SFLC) level and ratio. Results: Out of 4325 patients with symptomatic MM in the Swedish Myeloma Registry during 2008-2016 eligible for the study, 389 patients (9%) had non-measurable MM. Out of these, 253 patients (6%) had oligo-secretory and 136 (3%) had non-secretory MM. Median survival for secretory MM was 42.7 months, non-measurable MM 40.2 months, oligo-secretory MM 38.6 months, and non-secretory MM 44.6 months. Difference in overall observed survival was non-significant for all groups when compared with secretory MM. Within non-secretory MM, stem cell transplantation (SCT), 95% being auto-SCT, was significant for superior survival in multivariate analysis (HR 0.048. P =.0015). Conclusion: In this population-based study, we found no difference in survival between oligo- or non-secretory MM when compared with secretory MM. SCT appears to be important also for patients with non-secretory disease.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
amyloidosis, multiple myeloma, plasma cell neoplasms
in
European Journal of Haematology
volume
104
issue
5
pages
7 pages
publisher
Wiley-Blackwell
external identifiers
  • scopus:85083905693
  • pmid:31733147
ISSN
0902-4441
DOI
10.1111/ejh.13351
language
English
LU publication?
yes
id
ce3b7c9a-90d1-49b4-a50a-5b1d4f59c70d
date added to LUP
2020-05-19 07:28:29
date last changed
2024-04-03 06:51:08
@article{ce3b7c9a-90d1-49b4-a50a-5b1d4f59c70d,
  abstract     = {{<p>Objective: We describe survival in patients with oligo- and non-secretory multiple myeloma (MM). We refer to the whole group as non-measurable MM and compare it with secretory MM. Methods: Oligo-secretory MM was defined as M protein in serum &lt;10 g/L and M protein in urine &lt;200 measured as mg/day, mg/liter or mg/mmol creatinine. If patients had no M protein, they were defined as non-secretory. The groups were also subdivided by Free Light Chains (SFLC) level and ratio. Results: Out of 4325 patients with symptomatic MM in the Swedish Myeloma Registry during 2008-2016 eligible for the study, 389 patients (9%) had non-measurable MM. Out of these, 253 patients (6%) had oligo-secretory and 136 (3%) had non-secretory MM. Median survival for secretory MM was 42.7 months, non-measurable MM 40.2 months, oligo-secretory MM 38.6 months, and non-secretory MM 44.6 months. Difference in overall observed survival was non-significant for all groups when compared with secretory MM. Within non-secretory MM, stem cell transplantation (SCT), 95% being auto-SCT, was significant for superior survival in multivariate analysis (HR 0.048. P =.0015). Conclusion: In this population-based study, we found no difference in survival between oligo- or non-secretory MM when compared with secretory MM. SCT appears to be important also for patients with non-secretory disease.</p>}},
  author       = {{Wålinder, Göran and Samuelsson, Jan and Näsman, Per and Hansson, Markus and Juliusson, Gunnar and Forsberg, Karin and Svensson, Ronald and Linder, Olle and Carlson, Kristina and Kristinsson, Sigurdur Y. and Mellqvist, Ulf Henrik and Hveding Blimark, Cecilie and Turesson, Ingemar and Nahi, Hareth}},
  issn         = {{0902-4441}},
  keywords     = {{amyloidosis; multiple myeloma; plasma cell neoplasms}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{376--382}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{European Journal of Haematology}},
  title        = {{Outcome and characteristics of non-measurable myeloma : A cohort study with population-based data from the Swedish Myeloma Registry}},
  url          = {{http://dx.doi.org/10.1111/ejh.13351}},
  doi          = {{10.1111/ejh.13351}},
  volume       = {{104}},
  year         = {{2020}},
}